BridgeBio Pharma (NASDAQ:BBIO) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price target on […]

Related Keywords

United States , Arizona , American , Bridgebio Pharma , Raymond James , Bio Pharma , Kokusai Asset Management Co , Cantor Fitzgerald , Bridgebio Pharma Inc , Mitsubishi Ufj , Jpmorgan Chase Co , American International Group Inc , Nasdaq , Free Report , Moderate Buy , Get Free Report , State Retirement System , International Group , Asset Management , Bridgebio Pharma Daily ,